🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. Glatiramer Acetate

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    approved small molecule terminated

    5 trials

  2. Glivec 100 mg hard capsules, Tasigna 150 mg hard capsules

    Fondazione Telethon ETS

    Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)

    approved small molecule active

    1 trial

  3. Glucagon-like peptide-1 receptor agonist：Semaglutide

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    approved small molecule active

    1 trial

  4. Glycopyrronium in Combination With Tropisetron

    The First People's Hospital of Lianyungang

    Postoperative Nausea and Vomiting

    approved small molecule completed

    1 trial

  5. Guilingji Capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Oligospermia

    approved small molecule active

    1 trial

  6. Guli capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Knee Osteoarthritis

    approved small molecule active

    1 trial

  7. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Psoriatic Arthritis

    approved small molecule active

    1 trial

  8. HALOPERIDOL, CLOZAPINE, TIAPRIDE, SERTINDOLE, PALIPERIDONE, OLANZAPINE, SULPIRIDE, ARIPIPRAZOLE, LURASIDONE, RISPERIDONE, AMISULPRIDE, CHLORPROMAZINE, PIMOZIDE, QUETIAPINE

    Disc Medicine

    HAMLETT compares regular treatment guidelines for patients in remission after a first episode of psychosis, namely continuation with antipsychotic medication for at least one year, with early dose reduction/discontinuation.

    approved small molecule active

    1 trial

  9. HYDROXYCHLOROQUINE , ABATACEPT , AZATHIOPRINE , SULFASALAZINE , METHOTREXATE , Cimzia 200 mg solution for injection in pre-filled syringe, LEFLUNOMIDE, RoActemra 162 mg solution for injection in pre-filled syringe., RoActemra 20 mg/mL concentrate for solution for infusion, PREDNISOLONE , Triamcinolone Hexacetonide 20 mg/ml suspension for injection, METHOTREXATE

    The George Institute

    Rheumatoid Arthritis

    approved small molecule active

    1 trial

  10. Harvoni (Fixed dose combination ledipasvir/sofosbuvir)

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatitis C

    approved small molecule completed

    1 trial

  11. Henagliflozin Proline Tablets treatment

    The First People's Hospital of Lianyungang

    Diabetes Type 2

    approved small molecule active

    1 trial

  12. Hiconcil 500 mg trde kapsule, Enterol 250 mg, gélules, Matched Placebo will consist in caspules similar to the 250 mg capsules of the Saccharomyces boulardii CNCM-I-745 but with no active ingredient

    Biocodex

    Patients undergoing antibiotic therapy (in the context of erythema migrans (early skin form of Lyme borreliosis))

    approved small molecule active

    1 trial

  13. High-dose anrikefon

    The First People's Hospital of Lianyungang

    Laparoscopic Surgery

    approved small molecule active

    2 trials

  14. Honghe Fujie lotion

    The First People's Hospital of Lianyungang

    Bacterial Vaginitis

    approved small molecule active

    1 trial

  15. Humira 40 mg solution for injection in pre-filled pen, ORENCIA 125 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled syringe, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, ORENCIA 250 mg powder for concentrate for solution for infusion, Cosentyx 150 mg solution for injection in pre-filled syringe, Enbrel 25 mg solution for injection in pre-filled syringe, Simponi 45 mg/0.45 mL solution for injection in pre-filled pen., Jylamvo 2 mg/ml oral so

    Istituto Gentili S.r.l.

    Juvenile idiopathic arthritis

    approved small molecule active

    1 trial

  16. Hydroxychloroquine Sulfate

    The First People's Hospital of Lianyungang

    Primary IgA Nephropathy

    approved small molecule completed

    1 trial

  17. Hydroxychloroquine Sulfate 200 Mg Tablet

    The First People's Hospital of Lianyungang

    Atrial Fibrillation

    approved small molecule active

    1 trial

  18. Hylenex

    HALOZYME THERAPEUTICS, INC.

    Healthy

    approved small molecule completed

    2 trials

  19. ICS/LABA

    The First People's Hospital of Lianyungang

    Asthma

    approved small molecule active

    1 trial

  20. IMATINIB , PONATINIB , BOSUTINIB, NILOTINIB, DASATINIB

    Disc Medicine

    Chronic myeloid leukaemia

    approved small molecule active

    1 trial

  21. IMFINZI 50 mg/mL concentrate for solution for infusion., Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    AstraZeneca

    Advanced or recurrent endometrial cancer

    approved small molecule active

    1 trial

  22. IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., Rixathon 500 mg concentrate for solution for infusion, Bortezomib Hikma 3,5 mg Pulver zur Herstellung einer Injektionslösung, Rixathon 100 mg concentrate for solution for infusion, MTX HEXAL 2,5 mg Tabletten, -, Methotrexat-GRY® 50 mg/2 ml Injektionslösung, ASFOTASE ALFA

    Alexion Europe SAS

    HYPOPHOSPHATASIA

    approved small molecule active

    1 trial

  23. INCLISIRAN SODIUM, BEMPEDOIC ACID, ATORVASTATIN, ROSUVASTATIN, EZETIMIBE

    Novartis Pharmaceuticals

    Hypercholesterolemia

    approved small molecule active

    1 trial

  24. IPTACOPAN HYDROCHLORIDE, IPTACOPAN

    Novartis Pharmaceuticals

    C3 Glomerulopathy or idiopathic immune-complex membranoproliferative glomerulonephritis

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources